Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Niagen Bioscience Q3 2026 Results: Net Loss of $1.17M

Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.

Watch the Niagen Bioscience, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue27.234.0
Gross profit17.121.9
Profit before tax-1.24.8
Net income-1.24.6
EPS (diluted, $ a share)$-0.01$0.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-20.0%
Gross margin62.9%
Operating margin-5.8%
Source

10-Q filed with the SEC, NASDAQ: NAGE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Niagen Bioscience, Inc.: key numbers

Share price
$2.01Close, Nov 16
Market cap
$159M
Shares outstanding
79.2MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Niagen Bioscience, Inc.

All →
4:02 PM ET 8-K
Financial Results

Niagen Bioscience Financial Results

Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.

Term
Q3 2026

“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”

Rob Fried, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.